Literature DB >> 24879845

Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis.

Brahim Achour1, Jill Barber1, Amin Rostami-Hodjegan2.   

Abstract

Cytochrome P450 is a family of enzymes that catalyze reactions involved in the metabolism of drugs and other xenobiotics. These enzymes are therefore important in pharmacologic and toxicologic studies, and information on their abundances is of value in the process of scaling in vitro data to in vivo metabolic parameters. A meta-analysis was applied to data on the abundance of human hepatic cytochrome P450 enzymes in Caucasian adult livers (50 studies). Despite variations in the methods used to measure the abundance of enzymes, agreement between the studies in 26 different laboratories was generally good. Nonetheless, some heterogeneity was detected (Higgins and Thompson heterogeneity test). More importantly, large interindividual variability was observed in the collated data. Positive correlations between the expression levels of some cytochrome P450 enzymes were found in the abundance data, including the following pairs: CYP3A4/CYP3A5*1/*3 (Rs = 0.70, P < 0.0001, n = 52), CYP3A4/CYP2C8 (Rs = 0.68, P < 0.0001, n = 134), CYP3A4/CYP2C9 (Rs = 0.55, P < 0.0001, n = 71), and CYP2C8/CYP2C9 (Rs = 0.55, P < 0.0001, n = 99). These correlations can be used to demonstrate common genetic transcriptional mechanisms.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24879845     DOI: 10.1124/dmd.114.058834

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  56 in total

1.  Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability.

Authors:  Stephanie E Martinez; Jian Shi; Hao-Jie Zhu; Tania E Perez Jimenez; Zhaohui Zhu; Michael H Court
Journal:  Drug Metab Dispos       Date:  2019-08-19       Impact factor: 3.922

2.  Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper.

Authors:  Bhagwat Prasad; Brahim Achour; Per Artursson; Cornelis E C A Hop; Yurong Lai; Philip C Smith; Jill Barber; Jacek R Wisniewski; Daniel Spellman; Yasuo Uchida; Michael A Zientek; Jashvant D Unadkat; Amin Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2019-07-26       Impact factor: 6.875

3.  Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.

Authors:  Yingying Guo; Aroonrut Lucksiri; Gemma L Dickinson; Raj K Vuppalanchi; Janna K Hilligoss; Stephen D Hall
Journal:  Clin Pharmacol Ther       Date:  2019-09-12       Impact factor: 6.875

4.  Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.

Authors:  Felix Stader; Marco Siccardi; Manuel Battegay; Hannah Kinvig; Melissa A Penny; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

5.  CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches.

Authors:  Mary A Davis; Dustyn A Barnette; Noah R Flynn; Anirudh S Pidugu; S Joshua Swamidass; Gunnar Boysen; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2019-04-10       Impact factor: 3.739

6.  Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

7.  Comparative Proteomics Analysis of Human Liver Microsomes and S9 Fractions.

Authors:  Xinwen Wang; Bing He; Jian Shi; Qian Li; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2019-11-07       Impact factor: 3.922

8.  Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.

Authors:  Kosuke Doki; Adam S Darwich; Brahim Achour; Aleksi Tornio; Janne T Backman; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

9.  Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children.

Authors:  Elizabeth J Thompson; Huali Wu; Anil Maharaj; Andrea N Edginton; Stephen J Balevic; Marjan Cobbaert; Anthony P Cunningham; Christoph P Hornik; Michael Cohen-Wolkowiez
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

10.  Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.

Authors:  Yaofeng Cheng; Lifei Wang; Lisa Iacono; Donglu Zhang; Weiqi Chen; Jiachang Gong; William Griffith Humphreys; Jinping Gan
Journal:  Br J Clin Pharmacol       Date:  2017-10-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.